Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Schering's Three GMP Warning Letters In 1998 Counter Industry Decline

  • News

Executive Summary

Schering-Plough's receipt of three good manufacturing practices warning letters in 1998 joins a trend of multiple warning letters to big pharma in the face of an overall decline in drug compliance warning letters.

You may also be interested in...



Schering-Plough Clarinex NDA Approval Awaits Resolution Of GMP Problems

Schering-Plough's Clarinex (desloratadine) NDA will not be approved until the company answers FDA concerns regarding Good Manufacturing Practices compliance at a wide range of Schering operations.

Schering-Plough Clarinex NDA Approval Awaits Resolution Of GMP Problems

Schering-Plough's Clarinex (desloratadine) NDA will not be approved until the company answers FDA concerns regarding Good Manufacturing Practices compliance at a wide range of Schering operations.

Schering Implementing Four-Phase Proposal For Proventil Batch Release

Schering-Plough is implementing a four-phase proposal for Proventil (albuterol) batch release after receiving a warning letter from FDA July 21.

Table

View full table

Tags:
Latest Headlines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Global Pharma Guidance Tracker – March 2024

See All
UsernamePublicRestriction

Register

PS033786

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By